Unknown

Dataset Information

0

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.


ABSTRACT: BACKGROUND:The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis. METHODS:We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic, non-alcoholic steatohepatitis to assess treatment with obeticholic acid given orally (25 mg daily) or placebo for 72 weeks. Patients were randomly assigned 1:1 using a computer-generated, centrally administered procedure, stratified by clinical centre and diabetes status. The primary outcome measure was improvement in centrally scored liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least 2 points without worsening of fibrosis from baseline to the end of treatment. A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before end-of-treatment (72 weeks) biopsies supported the decision to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3). A planned interim analysis of the primary outcome showed improved efficacy of obeticholic acid (p=0·0024) and supported a decision not to do end-of-treatment biopsies and end treatment early in 64 patients, but to continue the trial to obtain the 24-week post-treatment measures. Analyses were done by intention-to-treat. This trial was registered with ClinicalTrials.gov, number NCT01265498. FINDINGS:Between March 16, 2011, and Dec 3, 2012, 141 patients were randomly assigned to receive obeticholic acid and 142 to placebo. 50 (45%) of 110 patients in the obeticholic acid group who were meant to have biopsies at baseline and 72 weeks had improved liver histology compared with 23 (21%) of 109 such patients in the placebo group (relative risk 1·9, 95% CI 1·3 to 2·8; p=0·0002). 33 (23%) of 141 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo group. INTERPRETATION:Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification. FUNDING:National Institute of Diabetes and Digestive and Kidney Diseases, Intercept Pharmaceuticals.

SUBMITTER: Neuschwander-Tetri BA 

PROVIDER: S-EPMC4447192 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri Brent A BA   Loomba Rohit R   Sanyal Arun J AJ   Lavine Joel E JE   Van Natta Mark L ML   Abdelmalek Manal F MF   Chalasani Naga N   Dasarathy Srinivasan S   Diehl Anna Mae AM   Hameed Bilal B   Kowdley Kris V KV   McCullough Arthur A   Terrault Norah N   Clark Jeanne M JM   Tonascia James J   Brunt Elizabeth M EM   Kleiner David E DE   Doo Edward E  

Lancet (London, England) 20141107 9972


<h4>Background</h4>The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis.<h4>Methods</h4>We did a multicentre, double-blind, placebo-controlled, parallel group, randomised clinical trial at medical centres in the USA in patients with non-cirrhotic,  ...[more]

Similar Datasets

| S-EPMC6920569 | biostudies-literature
| S-EPMC5931362 | biostudies-literature
| S-EPMC4696068 | biostudies-literature
| S-EPMC5221278 | biostudies-literature
| S-EPMC7267467 | biostudies-literature
| S-EPMC6752871 | biostudies-literature
| S-EPMC8652077 | biostudies-literature
2013-04-02 | E-GEOD-37031 | biostudies-arrayexpress
| S-EPMC10792533 | biostudies-literature
| S-EPMC8203497 | biostudies-literature